Paul Tudor Jones’s Syndax Pharmaceuticals SNDX Stock Holding History

Paul Tudor Jones’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69,059	Closed	-$1.61M	–	4220
2026 Q1	$1.61M	Buy	69,059 +21,638	+46%	+$470K	﹤0.01%	2009
2025 Q4	$996K	Sell	47,421 -2,763	-6%	-$48.2K	﹤0.01%	2275
2025 Q3	$772K	Sell	50,184 -2,872	-5%	-$37.6K	﹤0.01%	2440
2025 Q2	$497K	Sell	53,056 -13,932	-21%	-$153K	﹤0.01%	2606
2025 Q1	$823K	Buy	+66,988	New	+$945K	﹤0.01%	1943
2024 Q4	–	Sell	-43,070	Closed	-$829K	–	3473
2024 Q3	$829K	Sell	43,070 -4,083	-9%	-$84.4K	﹤0.01%	1737
2024 Q2	$968K	Buy	+47,153	New	+$987K	0.01%	1477
2024 Q1	–	Sell	-68,981	Closed	-$1.49M	–	2747
2023 Q4	$1.49M	Buy	68,981 +39,042	+130%	+$600K	0.01%	1256
2023 Q3	$435K	Buy	+29,939	New	+$566K	﹤0.01%	1740
2023 Q1	–	Sell	-16,581	Closed	-$422K	–	2916
2022 Q4	$422K	Buy	+16,581	New	+$387K	0.01%	1699

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Paul Tudor Jones's SNDX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 69,059 shares — an estimated $1.61M sold.

Paul Tudor Jones first reported a position in SNDX in Q4 2022 and held it in 10 quarters. The position peaked at $1.61M in Q1 2026. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Paul Tudor Jones reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 69,059 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.61M.
Paul Tudor Jones first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Paul Tudor Jones's Syndax Pharmaceuticals position peaked at $1.61M in Q1 2026.
240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.